Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2011 | Editorial Commentary

Diagnosis and therapy are walking together on radiopeptides’ avenue

Authors: Luigi Mansi, Irene Virgolini

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2011

Excerpt

The paper in this issue by Jiang et al. [1] stimulates a reflection on the state of the art and perspectives in radionuclide therapy, centred on the keyword “peptide”. The authors report their preliminary experience on the production of cystine knot peptides (knottins) 2.5D and 2.5F, engineered to bind with high affinity and specificity to integrin receptors, overexpressed on the surface of a variety of malignant human tumour cells and tumour neovasculature. In this study, 2.5D and 2.5F were successfully labelled with ¹⁷⁷Lu, representing potential therapeutic agents in a murine model of human glioma xenografts. …

Jiang L, Miao Z, Kimura RH, Liu H, Cochran JR, Culter CS, Bao A, Li P, Cheng Z. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging 2010. doi: 10.1007/s00259-010-1684-x.

Heute D, Kostron H, von Guggenberg E, Ingorokva S, Gabriel M, Dobrozemsky G, et al. Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC. J Nucl Med 2010;51(3):397–400.PubMedCrossRef

Gagnon MK, Hausner SH, Marik J, Abbey CK, Marshall JF, Sutcliffe JL. High-throughput in vivo screening of targeted molecular imaging agents. Proc Natl Acad Sci U S A 2009;106(42):17904–9.PubMedCrossRef

Lupetti A, Nibbering PH, Welling MM, Pauwels EK. Radiopharmaceuticals: new antimicrobial agents. Trends Biotechnol 2003;21(2):70–3.PubMedCrossRef

Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, et al. Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer’s disease and Down syndrome. Proc Natl Acad Sci U S A 2010;107(14):6538–43.PubMedCrossRef

Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med 2010;40(3):167–81.PubMedCrossRef

Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 2010;107(9):4311–6.PubMedCrossRef

Segala J, Engelman DM, Reshetnyak YK, Andreev OA. Accurate analysis of tumor margins using a fluorescent pH low insertion peptide (pHLIP). Int J Mol Sci 2009;10(8):3478–87.PubMedCrossRef

Kimura RH, Miao Z, Cheng Z, Gambhir SS, Cochran JR. A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem 2010 Feb 4

10.

Virgolini IJ, Gabriel M, von Guggenberg E, Putzer D, Kendler D, Decristoforo C. Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours. Eur J Cancer 2009;45 Suppl 1:274–91.PubMedCrossRef

11.

Mariani G, Erba PA, Signore A. Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs. J Nucl Med 2006;47(12):1904–7.PubMed

12.

Ambrosini V, Tomassetti P, Franchi R, Fanti S. Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010;54(1):16–23.PubMed

13.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508–18.PubMedCrossRef

14.

Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R, et al. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging 2010;54(1):52–60.PubMed

15.

King R, Surfraz MB, Finucane C, Biagini SC, Blower PJ, Mather SJ. 99mTc-HYNIC-gastrin peptides: assisted coordination of 99mTc by amino acid side chains results in improved performance both in vitro and in vivo. J Nucl Med 2009;50(4):591–8.PubMedCrossRef

16.

Boswell CA, Regino CA, Baidoo KE, Wong KJ, Milenic DE, Kelley JA, et al. A novel side-bridged hybrid phosphonate/acetate pendant cyclam: synthesis, characterization, and 64Cu small animal PET imaging. Bioorg Med Chem 2009;17(2):548–52.PubMedCrossRef

17.

Cascini GL, Cuccurullo V, Mansi L. The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology. Q J Nucl Med Mol Imaging 2010;54(1):24–36.PubMed

18.

Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010;54(1):68–75.PubMed

19.

Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15(1):61–9.PubMedCrossRef

20.

Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49 Suppl 2:113S–28S.PubMedCrossRef

21.

Krenning EP, Kooij PP, Bakker WH, Breeman WA, Postema PT, Kwekkeboom DJ, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci 1994;733:496–506.PubMedCrossRef

22.

Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudła B, de Herder WW, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009;90(2):220–6.PubMedCrossRef

23.

Kwekkeboom DJ, de Herder WW, van Eijck CHJ, Kam BL, van Essen M, Teunissen JJM, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumours. Semin Nucl Med 2010;40:78–88.PubMedCrossRef

24.

Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, von Guggenberg E, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 2010;54:92–9.PubMed

25.

Forrer F, Uusijärvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumours after treatment with 90Y-DOTATOC. J Nucl Med 2005;46:1310–16.PubMed

26.

Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, et al. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging 2010;54:84–91.PubMed

27.

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30.PubMedCrossRef

28.

Cwikla JB, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, et al. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Ann Oncol 2010;21(4):787–94.PubMedCrossRef

29.

Kratochwil C, Giesel FL, López-Benítez R, Schimpfky N, Kunze K, Eisenhut M, et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2010;16(10):2899–905.PubMedCrossRef

30.

Limouris GS, Chatziioannou A, Kontogeorgakos D, Mourikis D, Lyra M, Dimitriou P, et al. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 2008;35:1827–37.PubMedCrossRef

31.

McStay MKG, Maudgil D, Williams M, Tibballs JM, Watkinson AF, Caplin ME, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005;237:718–26.PubMedCrossRef

32.

Kalinowski M, Dressler M, König A, El-Sheik M, Rinke A, Höffken H, et al. Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion 2009;79(3):137–42.PubMedCrossRef

33.

Rinke A, Müller HH, Chade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27(28):4656–63.PubMedCrossRef

34.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50(9):1427–34.PubMedCrossRef

35.

Madsen MT, Bushnell DL, Juweid ME, Menda Y, O’Dorisio MS, O’Dorisio T, et al. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med 2006;47(4):660–7.PubMed

36.

Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. J Clin Oncol 2011 Jan 24 [Epub ahead of print].

Title: Diagnosis and therapy are walking together on radiopeptides’ avenue
Authors: Luigi Mansi
Irene Virgolini
Publication date: 01-04-2011
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1762-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Diagnosis and therapy are walking together on radiopeptides’ avenue

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2011

Favourable course of disease after incomplete remission on 131I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up

A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders

SPECT imaging evaluation in movement disorders: far beyond visual assessment

Portable gamma cameras: the real value of an additional view in the operating theatre

Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy

PET functional volume delineation: a robustness and repeatability study